Edesa Biotech, Inc.
EDSAEdesa Biotech is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for inflammatory and immune-related diseases.
Table of contents
Earnings
Next report
Aug 14, 2026 (in a month)Competitors
By market cap
By revenue growth
Profile
Edesa Biotech is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for inflammatory and immune-related diseases. The company targets unmet medical needs in respiratory and medical dermatology indications using mechanisms of action with human proof-of-concept. Its primary value proposition lies in its portfolio of host-directed therapeutics and monoclonal antibodies designed to modulate the body's immune response.
Edesa Biotech is a clinical-stage developer positioning itself as a leader in host-directed therapeutics for ARDS and vitiligo, leveraging significant government funding and exclusive intellectual property licenses.
Questions, answered.
- What is Edesa Biotech, Inc.'s market cap?
- Edesa Biotech, Inc. (EDSA) has a market capitalization of $67.6M and trades on NASDAQ.
- Who are Edesa Biotech, Inc.'s competitors?
- Edesa Biotech, Inc.'s key competitors include Regeneron Pharmaceuticals, Inc., Incyte Corporation, Pfizer Inc., and others. These companies compete in similar markets and product categories.
- Who does Edesa Biotech, Inc. partner with?
- Edesa Biotech, Inc.'s notable partners include BARDA, Government of Canada, Light Chain Bioscience, and others.
- What subsidiaries does Edesa Biotech, Inc. have?
- Edesa Biotech, Inc.'s subsidiaries include Edesa Biotech Research, Inc., Edesa Biotech USA, Inc..
- Where is Edesa Biotech, Inc. headquartered?
- Edesa Biotech, Inc. is headquartered in Canada and employs approximately 16 people. It has been publicly traded since 2010.